Answers are grounded in this paper and cite their sources.
Female patients undergoing thyroid surgery have a higher incidence of postoperative nausea and vomiting (PONV), and the effect of different opioids on PONV remains controversial. This study compares the effect of opioids with different durations of action on PONV in female patients undergoing thyroidectomy. This prospective observational study included 400 female patients undergoing elective thyroidectomy. Patients were divided into two groups based on the opioid used for anesthesia: the remifentanil group and the sufentanil group. All subjects received standardized triple antiemetic prophylaxis (dexamethasone, ondansetron, and diphenhydramine) and Ultrasound-guided bilateral superficial cervical plexus block. The primary outcome was the incidence of PONV within 48 h postoperatively. Secondary outcomes included the incidence and severity of postoperative nausea and postoperative vomiting within 48 h postoperatively, postoperative pain scores at rest and during coughing/swallowing within 48 h postoperatively. Potential modification of this association by a history of motion sickness was assessed by the interaction term between opioid use and history of motion sickness. Statistical tests were all two-sided, and P < 0.05 was considered statistically significant. The incidences and severity of postoperative nausea and postoperative vomiting in the remifentanil group during the short-term postoperative period (5–30 min after conscious extubation) and the long-term postoperative period (30min–48 h after conscious extubation) were lower than those in the sufentanil group, with statistically significant differences (all P < 0.05). The overall incidence of PONV in the remifentanil group within 48 h postoperatively was lower than that in the sufentanil group, and the difference was statistically significant (12.2% vs. 33.3%, P < 0.01). The interaction term between opioid type and history of motion sickness was not statistically significant (OR = 0.37, 95% CI 0.13–1.11, P = 0.08). Exploratory stratified analysis showed that among patients with a history of motion sickness, the remifentanil group had a lower incidence of PONV (OR = 0.19, 95% CI 0.08–0.41, P < 0.01); among patients without a history of motion sickness, this association persisted (OR = 0.43, 95% CI 0.19–0.97, P = 0.04). There was no statistically significant difference between the two groups in postoperative pain scores at fixed time points (all P > 0.05). Under a regimen combining triple antiemetic prophylaxis with Ultrasound-guided bilateral superficial cervical plexus block, remifentanil anesthesia was associated with a lower incidence of postoperative nausea and vomiting compared with sufentanil anesthesia. Exploratory stratified analysis based on opioid type and history of motion sickness demonstrated that the association of remifentanil with a lower incidence of PONV was present in patients both with and without a history of motion sickness. ChiCTR2500107369. Registration date: 2025-08-11. The trial was registered at the Chinese Clinical Trial Registry (http://www.chictr.org.cn).
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: